Suppr超能文献

贝特类药物对载脂蛋白A-I代谢的有益作用独立于任何过氧化物酶体增殖反应而发生。

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.

作者信息

Hennuyer N, Poulain P, Madsen L, Berge R K, Houdebine L M, Branellec D, Fruchart J C, Fiévet C, Duverger N, Staels B

机构信息

U325 INSERM, Département d'Athérosclérose, Institut Pasteur de Lille, France.

出版信息

Circulation. 1999 May 11;99(18):2445-51. doi: 10.1161/01.cir.99.18.2445.

Abstract

BACKGROUND

In humans, fibrates are frequently used normolipidemic drugs. Fibrates act by regulating genes involved in lipoprotein metabolism via activation of the peroxisome proliferator-activated receptor-alpha (PPARalpha) in liver. In rodents, however, fibrates induce a peroxisome proliferation, leading to hepatomegaly and possibly hepatocarcinogenesis. Although this peroxisome proliferative response appears not to occur in humans, it remains controversial whether the beneficial effects of fibrates on lipoprotein metabolism can occur dissociated from such undesirable peroxisomal response. Here, we assessed the influence of fenofibrate on lipoprotein metabolism and peroxisome proliferation in the rabbit, an animal that, contrary to rodents and similar to humans, is less sensitive to peroxisome proliferators.

METHODS AND RESULTS

First, we demonstrate that in normal rabbits, fenofibrate given at a high dose for 2 weeks does not influence serum concentrations or intestinal mRNA levels of the HDL apolipoprotein apoA-I. Therefore, the study was continued with human apoA-I transgenic rabbits that overexpress the human apoA-I gene under control of its homologous promoter, including its PPAR-response elements. In these animals, fenofibrate increases serum human apoA-I concentrations via an increased expression of the human apoA-I gene in liver. Interestingly, liver weight or mRNA levels and activity of fatty acyl-CoA oxidase, a rate-limiting and marker enzyme of peroxisomal beta-oxidation, remain unchanged after fenofibrate.

CONCLUSIONS

Expression of the human apoA-I transgene in rabbit liver suffices to confer fibrate-mediated induction of serum apoA-I. Furthermore, these data provide in vivo evidence that the beneficial effects of fibrates on lipoprotein metabolism occur mechanistically dissociated from any deleterious activity on peroxisome proliferation and possibly hepatocarcinogenesis.

摘要

背景

在人类中,贝特类药物是常用的血脂正常药物。贝特类药物通过激活肝脏中的过氧化物酶体增殖物激活受体α(PPARα)来调节参与脂蛋白代谢的基因。然而,在啮齿动物中,贝特类药物会诱导过氧化物酶体增殖,导致肝脏肿大并可能引发肝癌。尽管这种过氧化物酶体增殖反应似乎在人类中不会发生,但贝特类药物对脂蛋白代谢的有益作用是否能与这种不良的过氧化物酶体反应分离仍存在争议。在此,我们评估了非诺贝特对兔脂蛋白代谢和过氧化物酶体增殖的影响,兔这种动物与啮齿动物不同,与人类相似,对过氧化物酶体增殖剂不太敏感。

方法与结果

首先,我们证明在正常兔中,高剂量给予非诺贝特2周不会影响血清中高密度脂蛋白载脂蛋白apoA - I的浓度或肠道mRNA水平。因此,该研究继续在人apoA - I转基因兔中进行,这些兔在其同源启动子(包括其PPAR反应元件)的控制下过表达人apoA - I基因。在这些动物中,非诺贝特通过增加肝脏中人apoA - I基因的表达来提高血清中人apoA - I的浓度。有趣的是,非诺贝特处理后,肝脏重量、脂肪酸辅酶A氧化酶(过氧化物酶体β氧化的限速和标记酶)的mRNA水平及活性保持不变。

结论

人apoA - I转基因在兔肝脏中的表达足以赋予贝特类药物介导的血清apoA - I诱导作用。此外,这些数据提供了体内证据,表明贝特类药物对脂蛋白代谢的有益作用在机制上与对过氧化物酶体增殖及可能的肝癌发生的任何有害活性无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验